8-K: Biotricity Completes Additional Closing of Series B Preferred Stock, Raising $645,455

Biotricity Inc. has completed an additional closing of its Series B Preferred Stock, raising $645,455, bringing the total raised in this round to $2 million.

Summary

• Biotricity Inc. completed a third closing of its Series B Preferred Stock private placement, raising an additional $645,455.
• This closing was part of a larger agreement with an institutional investor, Ionic Ventures, LLC.
• The initial agreement, dated March 25, 2024, included a first closing of $1,000,000 and a second closing of $354,545.
• The total gross proceeds from the Series B Preferred Stock financing now amount to $2,000,000.
• The company has also filed an amendment to a registration statement to cover the resale of 2,095,238 shares of common stock issuable upon conversion of the Series B Preferred Stock.
• The company is obligated to seek stockholder approval for the conversion of the Series B Preferred Stock if required by Nasdaq rules.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company successfully completed the planned capital raise. However, there are some risks associated with the need for stockholder approval and the potential penalties for not meeting registration deadlines.

Positives

• The company successfully raised an additional $645,455 through the third closing of its Series B Preferred Stock.
• The total capital raised in this round reached $2,000,000, providing additional funding for the company.
• The investor's waiver of the 30-day closing deadline demonstrates flexibility and support for the company's financing efforts.

Negatives

• The company is obligated to seek stockholder approval for the conversion of the Series B Preferred Stock, which could introduce uncertainty.
• The company is obligated to issue 100,000 shares of common stock to the investor if it fails to meet deadlines for filing or effectiveness of the registration statement.

Risks

• Failure to obtain stockholder approval for the conversion of the Series B Preferred Stock could impact the financing.
• The company could be penalized with the issuance of 100,000 shares of common stock if it fails to meet the deadlines for the registration statement.
• The registration statement for the resale of common stock has not yet been declared effective by the SEC.

Future Outlook

The company will seek stockholder approval for the conversion of the Series B Preferred Stock if required by Nasdaq rules and will continue to work towards the effectiveness of the registration statement.

Management Comments

• The company has reaffirmed all obligations and liabilities under the Securities Purchase Agreement.

Industry Context

This private placement is a common method for biotech companies to raise capital, especially those in the development stage. The use of convertible preferred stock is a typical structure for such financings.

Comparison to Industry Standards

• Private placements of convertible preferred stock are a common financing method for companies like Biotricity, particularly in the biotech sector.
• The terms of the agreement, including the price per share and the conversion features, are generally consistent with industry standards for similar financings.
• Companies like Masimo and Dexcom, which are also in the medical technology space, have used similar financing methods to fund their growth and development.

Stakeholder Impact

• Shareholders may experience dilution upon conversion of the Series B Preferred Stock.
• The capital raise provides the company with additional funding, which could benefit employees and customers through continued operations and development.
• The company's creditors may benefit from the improved financial position.

Next Steps

• The company will seek stockholder approval for the conversion of the Series B Preferred Stock if required by Nasdaq rules.
• The company will continue to work towards the effectiveness of the registration statement.
• The company will deliver a certificate of good standing in California within ten business days.

Key Dates

Keywords

Private Placement, Series B Preferred Stock, Convertible Preferred Stock, Capital Raise, Registration Statement, Securities Purchase Agreement, Biotricity, Ionic Ventures